Ridgeback Biotherapeutics
E468969
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ridgeback Biotherapeutics canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T4784989 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ridgeback Biotherapeutics Context triple: [mAb114, sponsor, Ridgeback Biotherapeutics]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
-
D.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
E.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ridgeback Biotherapeutics Target entity description: Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
C.
Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
-
D.
Kymab
Kymab is a biotechnology company based in Cambridge, UK, focused on developing antibody-based therapeutics using its proprietary transgenic mouse platforms.
-
E.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
- F. None of above. chosen
Statements (34)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
private company ⓘ |
| aimsTo |
address unmet medical needs in infectious diseases
ⓘ
rapidly develop countermeasures for outbreaks ⓘ |
| businessModel |
drug development
ⓘ
partnered commercialization ⓘ |
| collaboratedWith | Merck & Co. ⓘ |
| countryOfOrigin |
United States
ⓘ
linked to:
United States of America
|
| developedProduct | molnupiravir ⓘ |
| developsTreatmentFor |
COVID-19
ⓘ
linked to:
COVID-19 pandemic
Ebola virus disease ⓘ serious infectious diseases ⓘ |
| focusesOn |
antiviral therapeutics
ⓘ
emerging viral diseases ⓘ immunotherapy ⓘ infectious diseases ⓘ |
| foundedBy |
Wayne Holman
ⓘ
Wendy Holman ⓘ |
| hasKeyPerson | Wendy Holman ⓘ |
| headquartersLocation | Miami, Florida, United States ⓘ |
| indicationOfProduct | treatment of COVID-19 ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| licensingActivity | licensed molnupiravir to Merck & Co. ⓘ |
| productType | oral antiviral drug ⓘ |
| researchArea |
RNA virus infections
ⓘ
biodefense-related pathogens ⓘ pandemic preparedness ⓘ |
| roleOfKeyPerson | Chief Executive Officer ⓘ |
| targetMarket |
global health
ⓘ
public health emergencies ⓘ |
| therapeuticModality |
immunotherapies
ⓘ
small-molecule antivirals ⓘ |
| worksOn | therapeutics for viral hemorrhagic fevers ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ridgeback Biotherapeutics Description of subject: Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.